Tolvaptan-d<sub>7</sub>

Tolvaptan-d7

CAT N°: 26453
Price:

From 146.00 124.10

Tolvaptan-d7 is intended for use as an internal standard for the quantification of tolvaptan (Item No. 19691) by GC- or LC-MS. Tolvaptan is a nonpeptide vasopressin V2 receptor antagonist (IC50 = 3 nM for rat receptor) and a diuretic agent.{31703} It is selective for V2 over V1 receptors (IC50 = 0.58 ?M). Tolvaptan increases urine volume by 3-fold in rats when administered at a dose of 0.54 mg/kg. It also reduces left ventricular end-systolic volumes and improves left ventricular ejection fraction in a rat model of myocardial infarction.{43556} Formulations containing tolvaptan have been used to treat hyponatremia.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-6-(methyl-d3)-benzamide-2,3,4,5-d4
  • Correlated keywords
    • deuterated deuterium non-peptide V-1 2 OPC 41061 OPC41061 GCMS LCMS
  • Product Overview:
    Tolvaptan-d7 is intended for use as an internal standard for the quantification of tolvaptan (Item No. 19691) by GC- or LC-MS. Tolvaptan is a nonpeptide vasopressin V2 receptor antagonist (IC50 = 3 nM for rat receptor) and a diuretic agent.{31703} It is selective for V2 over V1 receptors (IC50 = 0.58 ?M). Tolvaptan increases urine volume by 3-fold in rats when administered at a dose of 0.54 mg/kg. It also reduces left ventricular end-systolic volumes and improves left ventricular ejection fraction in a rat model of myocardial infarction.{43556} Formulations containing tolvaptan have been used to treat hyponatremia.

We also advise you